Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: Reversing a pattern of failure

Oncologist

Volumn 8, Issue 4, 2003, Pages 350-360

  Argiris, Athanassios ^a   Haraf, Daniel J ^b,c   Kies, Merrill S ^a   Vokes, Everett E ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c University of Chicago   (United States)

Author keywords

5 FU; Chemotherapy; Head and neck cancer; Hydroxyurea; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IFOSFAMIDE; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DERMATITIS; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; EDUCATION, MEDICAL, CONTINUING; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0041707983     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-4-350     Document Type: Article

References (59)

1. Argiris A. Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol 2002;14:323-329.
2. Hong WK, Bromer R. Chemotherapy in head and neck cancer. N Engl J Med 1983;308:75-79.
3. Moran RG, Danenberg PV, Heidelberger C. Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochem Pharmacol 1982;31:2929-2935.
4. Frankfurt OS. Enhancement of the antitumor activity of 5-fluorouracil by drug combinations. Cancer Res 1973;33:1043-1047.
5. Vokes EE, Haraf DJ, Panje WR et al. Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol 1992;19:53-58.
6. Vokes EE. Interactions of chemotherapy and radiation. Semin Oncol 1993;20:70-79.
7. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990;8:911-934.
8. Vokes EE, Beckett M, Karrison T et al. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology 1992;49:454-460.
9. Lo TC, Wiley AL Jr, Ansfield FJ et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol 1976;126:229-235.
10. Browman GP, Cripps C, Hodson DI et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994;12:2648-2653.
11. Sanchiz F, Milla A, Torner J et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347-1350.
12. Stefani S, Eells RW, Abbate J. Hydroxyurea and radiotherapy in head and neck cancer. Results of a prospective controlled study in 126 patients. Radiology 1971;101:391-396.
13. Richards GJ Jr, Chambers RG. Hydroxyurea: a radiosensitizer in the treatment of neoplasms of the head and neck. Am J Roentgenol Radium Ther Nucl Med 1969;105:555-565.
14. Hussey DH, Abrams JP. Combined therapy in advanced head and neck cancer: hydroxyurea and radiotherapy. Prog Clin Cancer 1975;6:79-86.
15. Stefani S, Chung TS. Hydroxyurea and radiotherapy in head and neck cancer - long term results of a double blind randomized prospective study. Radiat Oncol Biol Phys 1980;6:1398a.
16. Piver MS, Barlow JJ, Vongtama V et al. Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix. A randomized double-blind study. Am J Obstet Gynecol 1983;147:803-808.
17. Rose PG. Chemoradiotherapy for cervical cancer. Eur J Cancer 2002;38:270-278.
18. Vokes EE, Panje WR, Schilsky RL et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989;7:761-768.
19. Byfield JE, Sharp TR, Frankel SS et al. Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck. J Clin Oncol 1984;2:406-413.
20. Taylor SG 4th, Murthy AK, Showel JL et al. Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy. Cancer Treat Rep 1985;69:933-939.
21. Haraf DJ, Vokes EE, Weichselbaum RR et al. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope 1992;102:630-636.
22. Vokes EE, Haraf DJ, Mick R et al. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994;12:2351-2359.
23. Brockstein B, Haraf DJ, Stenson K et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating, factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998;16:735-744.
24. Brockstein B, Haraf DJ, Stenson K et al. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol 2000;11:721-728.
25. Parsons JT, Mendenhall WM, Cassisi NJ et al. Hyperfractionation for head and neck cancer. Int J Radiat Oncol Biol Phys 1988;14:649-658.
26. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
27. Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer - the time factor. Int J Radiat Oncol Biol Phys 1997;39:831-836.
28. Amdur RJ, Parsons JT, Mendenhall WM et al. Split-course versus continuous-course irradiation in the postoperative setting for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1989;17:279-285.
29. Keane TJ, Cummings BJ, O'Sullivan B et al. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys 1993;25:613-618.
30. Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
31. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
32. Taylor SG 4th, Murthy AK, Vannetzel JM et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994;12:385-395.
33. Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
34. Vokes EE, Kies M, Haraf DJ et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13:876-883.
35. Kies MS, Haraf DJ, Athanasiadis I et al. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 1998;16:2715-2721.
36. Shin DM, Glisson BS, Khuri FR et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;95:322-330.
37. Colevas AD, Norris CM, Tishler RB et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999;17:3503-3511.
38. Posner MR, Glisson B, Frenette G et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096-1104.
39. Garden AS, Pajak TF, Vokes E et al. Preliminary data of RTOG 9703 - a phase II randomized trial of concurrent radiation and chemotherapy for advanced squamous cell of the head and neck. Proc Am Soc Clin Oncol 2001;20:A891.
40. De Crevoisier R, Domenge C, Wibault P et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 2001;91:2071-2076.
41. Wheeler RH, Harris J, Spencer S et al. RTOG 9610: Phase II study of reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck: survival results. Proc Am Soc Clin Oncol 2001;20:A887.
42. Gandia D, Wibault P, Guillot T et al. Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer. Head Neck 1993;15:8-15.
43. Haraf DJ, Kies M, Rademaker AW et al. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol 1999;17:638-644.
44. Vokes EE, Kies MS, Haraf DJ et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-1661.
45. Vokes EE, Haraf DJ, Brockstein BE et al. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol 1999;9(suppl 1):70-76.
46. Kies MS, Haraf DJ, Rosen F et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961-1969.
47. Vokes EE, Stenson K, Rosen FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003;21:320-326.
48. Rosen FR, Haraf D, Brockstein B et al. Multicenter randomized phase II study of 1 hour infusion paclitaxel, fluorouracil and hydroxyurea with concomitant hyperfractionated radiotherapy with or without erythropoietin for advanced head and neck cancer. Proc Am Soc Clin Oncol 2001;20:A902.
49. Vokes EE, Moormeier JA, Ratain MJ et al. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol 1992;29:178-184.
50. Dische S, Saunders M. The rationale for continuous, hyperfractionated, accelerated radiotherapy (CHART). Int J Radiat Oncol Biol Phys 1990;19:1317-1320.
51. Horiot JC, Bontemps P, van den Bogaert W et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-121.
52. Hong WK, Bromer RH, Amato DA et al. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 1985;56:1242-1245.
53. List MA, Siston A, Haraf D et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol 1999;17:1020-1028.
54. List MA, Haraf D, Stracks J et al. Quality of life/performance in head & neck cancer: comparison between paclitaxel-based and cisplatin-based concomitant chemoradiotherapy regimens. Proc Am Soc Clin Oncol 2000;19:A1625.
55. Brockstein BE, Haraf DJ, Kies MS et al. Survival, patterns of failure, and risk factors for recurrence after intensive concomitant chemoradiation (CRT) for squamous cell head and neck cancer (SCHNC). Proc Am Soc Clin Oncol 2002;21:A918.
56. Adelstein DJ, Saxton JP, Lavertu P et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 2002;20:1405-1410.
57. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272.
58. Posner MR, Colevas AD, Tishler RB. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol 2000;27:13-24.
59. Haddad R, Colevas AD, Tishler R et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 2003;97:412-418.